Verona Pharma plc (NASDAQ:TARA) Major Shareholder Sells $49,547.60 in Stock

Verona Pharma plc (NASDAQ:TARA) major shareholder Randall Marshall sold 2,554 shares of the company’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $19.40, for a total value of $49,547.60. Following the transaction, the insider now directly owns 586,074 shares in the company, valued at approximately $11,369,835.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Randall Marshall also recently made the following trade(s):

  • On Thursday, September 10th, Randall Marshall sold 239 shares of Verona Pharma stock. The stock was sold at an average price of $18.00, for a total value of $4,302.00.
  • On Tuesday, September 8th, Randall Marshall sold 3,108 shares of Verona Pharma stock. The stock was sold at an average price of $18.94, for a total value of $58,865.52.
  • On Wednesday, September 2nd, Randall Marshall sold 207 shares of Verona Pharma stock. The shares were sold at an average price of $20.68, for a total transaction of $4,280.76.
  • On Friday, August 28th, Randall Marshall sold 771 shares of Verona Pharma stock. The shares were sold at an average price of $22.09, for a total transaction of $17,031.39.
  • On Monday, August 24th, Randall Marshall sold 974 shares of Verona Pharma stock. The shares were sold at an average price of $23.16, for a total transaction of $22,557.84.
  • On Thursday, August 20th, Randall Marshall sold 510 shares of Verona Pharma stock. The shares were sold at an average price of $24.18, for a total transaction of $12,331.80.
  • On Monday, August 17th, Randall Marshall sold 1,548 shares of Verona Pharma stock. The shares were sold at an average price of $25.11, for a total transaction of $38,870.28.
  • On Friday, August 14th, Randall Marshall sold 700 shares of Verona Pharma stock. The shares were sold at an average price of $25.09, for a total transaction of $17,563.00.
  • On Wednesday, July 29th, Randall Marshall sold 2,516 shares of Verona Pharma stock. The shares were sold at an average price of $26.42, for a total transaction of $66,472.72.
  • On Monday, July 27th, Randall Marshall sold 338 shares of Verona Pharma stock. The shares were sold at an average price of $26.08, for a total transaction of $8,815.04.

Shares of TARA traded up $0.03 during trading hours on Wednesday, reaching $19.44. The stock had a trading volume of 726 shares, compared to its average volume of 20,451. Verona Pharma plc has a 52 week low of $8.80 and a 52 week high of $67.08. The firm has a 50-day moving average of $22.87 and a 200 day moving average of $27.62.

Verona Pharma (NASDAQ:TARA) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.22) EPS for the quarter. On average, equities research analysts expect that Verona Pharma plc will post -3.31 earnings per share for the current fiscal year.

Several brokerages have commented on TARA. Zacks Investment Research upgraded shares of Verona Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, July 15th. Guggenheim began coverage on shares of Verona Pharma in a research report on Wednesday, July 29th. They issued a “buy” rating and a $50.00 price objective for the company.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TARA. American International Group Inc. acquired a new position in Verona Pharma in the 2nd quarter worth $36,000. Citigroup Inc. acquired a new position in Verona Pharma in the 1st quarter worth $43,000. New York State Common Retirement Fund acquired a new position in Verona Pharma in the 2nd quarter worth $94,000. Knott David M boosted its stake in Verona Pharma by 45.5% in the 2nd quarter. Knott David M now owns 3,835 shares of the company’s stock worth $112,000 after purchasing an additional 1,200 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in Verona Pharma in the 1st quarter worth $184,000. Institutional investors and hedge funds own 67.69% of the company’s stock.

About Verona Pharma

ArTara Therapeutics, Inc develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.

Recommended Story: How does a dividend reinvestment plan work?

Insider Buying and Selling by Quarter for Verona Pharma (NASDAQ:TARA)

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.